Top-News

Array BioPharma News

Keine aktuellen Kursdaten verfügbar
WKN: 580564
ISIN: US04269X1054
Typ: Aktie

Array BioPharma News

13.07.19 - The Motley Fool
Pfizer steht vor dem Umsatzeinbruch – trotzdem solltest du die Aktie mögen
Einige Investitionsentscheidungen scheinen echte Selbstläufer zu sein. Wenn man absehen kann, dass das Umsatzwachstum eines Unternehmens sinken wird, dann lässt man ...
06.07.19 - PR Newswire
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...
27.06.19 - PR Newswire
Lifshitz & Miller LLP Announces Investigation of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., and Raytheon Company, Shutterfly, Inc., Sotheby's and Stewardship Financial Corporation, and Zimmer Biomet Holdings, Inc.
Lifshitz & Miller LLP Announces Investigation of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., and Raytheon Company, Shutterfly, Inc., Sotheby's ...
25.06.19 - PR Newswire
Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic ...
20.06.19 - PR Newswire
Thinking about trading options or stock in Array Biopharma, JPMorgan Chase, Coca-Cola, Match Group, or Netflix?
Thinking about trading options or stock in Array Biopharma, JPMorgan Chase, Coca-Cola, Match Group, or Netflix? PR Newswire
18.06.19 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition
SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition PR Newswire
17.06.19 - PR Newswire
Thinking about buying stock in Aurora Cannabis, Array Biopharma, Beyond Meat, Dare Bioscience, or Uniqure?
Thinking about buying stock in Aurora Cannabis, Array Biopharma, Beyond Meat, Dare Bioscience, or Uniqure? PR Newswire
17.06.19 - Der Aktionär
Biotech-Wahnsinn: Pfizer greift nach Array BioPharma - über 60% Aufschlag!
17.06.19 - dpa-AFX
US-Pharmakonzern Pfizer will Biotech-Geschäft durch Milliarden-Zukauf stärken
Der US-​Pharmakonzern Pfizer will sein Biopharmazeutika-​Geschäft durch einen Milliarden-​Zukauf ausbauen. Für 48 US-Dollar je Aktie in bar will der Konzern den Biotechnologie-...
17.06.19 - PR Newswire
Pfizer to Acquire Array BioPharma
Pfizer to Acquire Array BioPharma - Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in ...
04.06.19 - PR Newswire
Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference PR Newswire
29.05.19 - PR Newswire
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference PR Newswire
29.05.19 - PR Newswire
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-​mutant Melanoma at 2019 ...
21.05.19 - PR Newswire
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of ...
09.05.19 - PR Newswire
Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire
07.05.19 - PR Newswire
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019 - Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million ...
18.03.19 - PR Newswire
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer ...
05.03.19 - PR Newswire
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference PR Newswire
21.02.19 - PR Newswire
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference PR Newswire
05.02.19 - PR Newswire
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019 - Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million ...

Newssuche

Videos

newspaper
18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »